Verano Holdings (VRNO) Other Non-Current Liabilities (2022 - 2026)
Verano Holdings' (VRNO) quarterly Other Non-Current Liabilities came in at $1.5 million in Q1 2026, down 37.99% year-on-year from $2.5 million in Q1 2025, and up 42.37% on a QoQ basis from $1.1 million in Q4 2025.
Verano Holdings (VRNO) Other Non-Current Liabilities (2022 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 5 years of Other Non-Current Liabilities data on file, last reported at $1.5 million in Q1 2026.
- On a quarterly basis, Other Non-Current Liabilities fell 37.99% year-over-year to $1.5 million in Q1 2026; TTM through Mar 2026 was $1.5 million, a 37.99% decrease from a year earlier, with the FY2025 full-year figure at $1.1 million, down 43.43% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $1.5 million, up from $1.1 million in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for VRNO reached as high as $66.9 million in Q2 2022 and fell as low as $255000.0 in Q4 2023.
- Historically, Other Non-Current Liabilities has averaged $10.3 million across 5 years, with a median of $3.5 million in 2024.
- Across the five-year window, Other Non-Current Liabilities sank 95.75% in 2023 and surged 649.41% in 2024, its largest moves.
- Year by year, Other Non-Current Liabilities stood at $6.0 million in 2022, then sank by 95.75% to $255000.0 in 2023, then jumped by 649.41% to $1.9 million in 2024, then sank by 43.43% to $1.1 million in 2025, then soared by 42.37% to $1.5 million in 2026.
- Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $1.5 million in Q1 2026, $1.1 million in Q4 2025, and $2.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Verano Holdings | 2.02 Bn | 1.94 Bn | 98.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.54 Mn |
| Dec 31, 2025 | 1.08 Mn |
| Sep 30, 2025 | 2.16 Mn |
| Jun 30, 2025 | 1.42 Mn |
| Mar 31, 2025 | 2.48 Mn |
| Dec 31, 2024 | 1.91 Mn |
| Sep 30, 2024 | 5.01 Mn |
| Jun 30, 2024 | 3.78 Mn |
| Mar 31, 2024 | 3.24 Mn |
| Dec 31, 2023 | 255,000.00 |
| Sep 30, 2023 | 4.95 Mn |
| Jun 30, 2023 | 4.95 Mn |
| Mar 31, 2023 | 5.74 Mn |
| Dec 31, 2022 | 5.99 Mn |
| Sep 30, 2022 | 53.74 Mn |
| Jun 30, 2022 | 66.90 Mn |